Arcadia Biosciences (RKDA) Trades at $0.33 After Triangle; Clearwater Paper (CLW) Sellers Increased By 41.92% Their Shorts

October 11, 2017 - By Darrin Black

Clearwater Paper Corporation (NYSE:CLW) had an increase of 41.92% in short interest. CLW’s SI was 383,900 shares in October as released by FINRA. Its up 41.92% from 270,500 shares previously. With 78,800 avg volume, 5 days are for Clearwater Paper Corporation (NYSE:CLW)’s short sellers to cover CLW’s short positions. The SI to Clearwater Paper Corporation’s float is 2.37%. The stock increased 0.22% or $0.1 on October 10, reaching $45. About shares traded. Clearwater Paper Corp (NYSE:CLW) has declined 24.41% since October 11, 2016 and is downtrending. It has underperformed by 41.11% the S&P500.

Arcadia Biosciences Inc (RKDA) formed triangle with $0.35 target or 5.00% above today’s $0.33 share price. Arcadia Biosciences Inc (RKDA) has $14.19M valuation. It closed at $0.333 lastly. It is down 43.32% since October 11, 2016 and is downtrending. It has underperformed by 60.02% the S&P500.

Among 4 analysts covering Clearwater Paper (NYSE:CLW), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Clearwater Paper had 14 analyst reports since September 18, 2015 according to SRatingsIntel. The stock of Clearwater Paper Corp (NYSE:CLW) has “Hold” rating given on Sunday, October 8 by RBC Capital Markets. The stock has “Sector Perform” rating by RBC Capital Markets on Thursday, February 11. As per Thursday, August 3, the company rating was maintained by RBC Capital Markets. As per Thursday, May 12, the company rating was downgraded by DA Davidson. Vertical Research downgraded the stock to “Hold” rating in Friday, July 22 report. The rating was maintained by RBC Capital Markets with “Sector Perform” on Friday, July 22. The firm has “Underperform” rating given on Friday, January 6 by RBC Capital Markets. The stock of Clearwater Paper Corp (NYSE:CLW) has “Hold” rating given on Friday, September 22 by KeyBanc Capital Markets. The firm earned “Hold” rating on Monday, September 4 by RBC Capital Markets. The firm has “Sector Perform” rating given on Tuesday, January 12 by RBC Capital Markets.

Investors sentiment increased to 1.21 in 2017 Q2. Its up 0.31, from 0.9 in 2017Q1. It increased, as 10 investors sold Clearwater Paper Corp shares while 46 reduced holdings. 18 funds opened positions while 50 raised stakes. 13.81 million shares or 2.34% less from 14.14 million shares in 2017Q1 were reported. Louisiana State Employees Retirement Systems has invested 0.02% in Clearwater Paper Corp (NYSE:CLW). Qs Invsts Limited Liability holds 63,150 shares or 0.03% of its portfolio. Us National Bank & Trust De holds 1,637 shares. Great West Life Assurance Can has 23,996 shares. Ameriprise Financial reported 104,308 shares. Loomis Sayles And Co L P holds 0% or 171 shares in its portfolio. Pinebridge Invests L P, a New York-based fund reported 23,394 shares. New York State Teachers Retirement Sys holds 0.01% or 54,472 shares in its portfolio. Da Davidson And has 0% invested in Clearwater Paper Corp (NYSE:CLW) for 64 shares. Davidson Investment Advsr has invested 0.01% in Clearwater Paper Corp (NYSE:CLW). Paloma Partners Mgmt reported 5,243 shares. Renaissance Technology Limited Liability Corp invested in 0% or 52,325 shares. Virginia Retirement Et Al accumulated 15,384 shares or 0.01% of the stock. California Pub Employees Retirement Sys has invested 0.01% of its portfolio in Clearwater Paper Corp (NYSE:CLW). M&R Capital Mngmt Inc reported 1,300 shares.

Clearwater Paper Corporation manufactures consumer tissue, away-from-home tissue, parent roll tissue, bleached paperboard and pulp at manufacturing facilities across the nation. The company has market cap of $739.50 million. The Firm operates through two divisions: Consumer Products segment, and Pulp and Paperboard segment. It has a 29.04 P/E ratio. The Company’s Consumer Products segment makes and sells a line of at-home tissue products, as well as AFH products.

Analysts await Arcadia Biosciences Inc (NASDAQ:RKDA) to report earnings on November, 9. They expect $-0.08 EPS, up 11.11% or $0.01 from last year’s $-0.09 per share. After $-0.09 actual EPS reported by Arcadia Biosciences Inc for the previous quarter, Wall Street now forecasts -11.11% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Darrin Black




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: